Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)

Learn more about:
Related Clinical Trial
Retrospective Register for Uveal Melanoma Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma Adjuvant Melatonin for Uveal Melanoma Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) The Role of Genetic Mutations and of Circulating mRNAs in Uveal Melanoma A Study of Concurrent Stereotactic Body Radiotherapy With Ipi and Nivo in Metastatic Uveal Melanoma Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma Managed Access Program Supporting Patient Access to Tebentafusp Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Early Integration of Supportive Care Into Standard Oncology Care for Metastatic Uveal Melanoma Patients Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal Melanoma Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma A Prospective Natural History Study in Uveal Melanoma Uveal Melanoma and Brachytheraphy: Long-term Outcomes. A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) Phase 2 Trial of AU-011 Via Suprachoroidal Administration With a Dose Escalation and Randomized, Masked Dose Expansion Designed to Evaluate Safety and Efficacy of AU-011 in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery A Study of PLX2853 in Advanced Malignancies. Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519) Treatment Of Radiation Retinopathy Trial Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Study in Subjects With Small Primary Choroidal Melanoma Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Trial of AEB071 in Combination With BYL719 in Patients With Melanoma Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF Vorinostat in Treating Patients With Metastatic Melanoma of the Eye Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma Pembrolizumab in Treating Patients With Advanced Uveal Melanoma Vascular Response to Brachytherapy Using Functional OCT Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser) Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma New Biopsy Technique for Uveal Melanoma Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy Intermittent Selumetinib for Uveal Melanoma Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0) Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma Vorinostat in Patients With Class 2 High Risk Uveal Melanoma Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases A Phase II Study of BVD-523 in Metastatic Uveal Melanoma Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma Treatment With Intravitreal Avastin for Large Uveal Melanomas

Brief Title

Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)

Official Title

A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)

Brief Summary

      Selumetinib therapy in patients with metastatic uveal melanoma.
    

Detailed Description

      A randomised double-blind study to assess the efficacy of selumetinib (AZD6244, Hyd-Sulfate)
      in combination with Dacarbazine compared with placebo in combination with Dacarbazine as
      first systemic therapy in patients with metastatic uveal melanoma (SUMIT)
    

Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Assessment of the Efficacy of Selumetinib in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine Measured as Progression Free Survival (PFS) Using BICR According to RECIST 1.1.

Secondary Outcome

 Assessment of the Efficacy of Selumetinib in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine in Terms of Objective Response Rate (ORR) by BICR

Condition

Metastatic

Intervention

75mg selumetinib

Study Arms / Comparison Groups

 selumetinib 75mg twice daily
Description:  selumetinib 75mg twice daily in combination with dacarbazine.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

152

Start Date

April 2014

Completion Date

October 2016

Primary Completion Date

May 2015

Eligibility Criteria

        Inclusion Criteria: Clinical diagnosis of metastatic uveal melanoma; Written consent from
        female or male patients aged 18 years and over. Histological or cytological confirmation of
        melanoma who are suitable for treatment with dacarbazine chemotherapy.

          -  At least one lesion that can be accurately measured at baseline as>/=10mm in the
             longest diameter. (except lymph nodes which must have short axis ≥15 mm) with CT or
             MRI and which is suitable for accurate repeated measurements

          -  ECOG performance status 0-1

          -  life expectancy >12 weeks

          -  Normal organ and marrow function

          -  Evidence of post-menopausal status, or negative urinary or serum pregnancy test for
             female pre-menopausal patients

          -  Patients should be able to swallow selumetinib/placebo capsules

        Exclusion Criteria:-Involvement in the planning and/or conduct of the study (applies to
        both AstraZeneca staff and/or staff at the study site)

          -  Previous randomisation in the present study

          -  Patients cannot have previously been treated with a systemic anti-cancer therapy.
             Patients can have prior intra-hepatic or non-systemic therapy. -Having received any of
             the following within the specified timeframe:

        Any prior systemic anti-cancer therapy for the treatment of this current diagnosis, An
        investigational drug within 30 days of starting treatment or within five half-lives of the
        compound (whichever is the most appropriate is at the discretion of the Investigator), or
        have not recovered from side effects of an investigational drug Any non-systemic
        anti-cancer therapy which has not been cleared from the body by the time of starting study
        treatment Radiation therapy within 4 weeks prior to starting study treatment, or limited
        field of radiation for palliation within 7 days of the first dose of study treatment Major
        surgery within 4 weeks prior to entry into the study (excluding the placement of vascular
        access) which would prevent administration of study treatment, Any prior investigational
        therapy comprising inhibitors of RAS, RAF or MEK at any time, Previous treatment with
        dacarbazine. Any unresolved toxicity >CTCAE grade 2 from previous anti-cancer therapy,
        excluding alopecia -History of allergic reactions attributed to compounds of similar
        chemical or biologic composition to selumetinib or dacarbazine

        --Symptomatic brain metastases or spinal cord compression (patients must be treated and
        stable off steroids and anti-convulsants for at least 1 month prior to entry into the
        study)

        Cardiac conditions as follows:

          -  Uncontrolled hypertension (BP ≥150/95 mmHg despite medical therapy)

          -  Acute coronary syndrome within 6 months prior to starting treatment

          -  Uncontrolled Angina - Canadian Cardiovascular Society grade II-IV despite medical
             therapy - Symptomatic heart failure (New York Heart Association [NYHA] Class II-IV,-
             Prior or current cardiomyopathy

          -  Baseline LVEF <55% measured by echocardiography or MUGA. Appropriate correction to be
             used if a MUGA is performed

          -  Severe valvular heart disease

          -  Atrial fibrillation with a ventricular rate >100 bpm on ECG at rest

          -  QTcF >450 ms or other factors that increase the risk of QTc prolongation

          -  Any evidence of severe or uncontrolled systemic disease, active infection, active
             bleeding diatheses or renal transplant, including any patient known to have hepatitis
             B, hepatitis C or human immunodeficiency virus (HIV)

          -  Refractory nausea and vomiting, chronic gastrointestinal diseases (eg inflammatory
             bowel disease), or significant bowel resection that would preclude adequate absorption

          -  History of another primary malignancy within 5 years prior to starting study
             treatment, except for adequately treated basal or squamous cell carcinoma of the skin
             or cancer of the cervix in situ and the disease under study

          -  Ophthalmologic conditions:

          -  Current or past history of central serous retinopathy

          -  Current or past history of retinal vein occlusion

          -  IOP >21 mmHg or uncontrolled glaucoma (irrespective of IOP)

          -  Female patients who are breast-feeding a child and male or female patients of
             reproductive potential who are not employing an effective method of birth control

          -  Clinical judgement by the Investigator that the patient should not participate in the
             study.
      

Gender

All

Ages

18 Years - 130 Years

Accepts Healthy Volunteers

No

Contacts

, , 

Location Countries

Belgium

Location Countries

Belgium

Administrative Informations


NCT ID

NCT01974752

Organization ID

D1344C00001


Responsible Party

Sponsor

Study Sponsor

AstraZeneca


Study Sponsor

, , 


Verification Date

January 2017